InsidersTradesSigma
INTRASENSE Stock: price and directors' dealings · France · AMF
Track the INTRASENSE share price and the full insider trade history of the company, a listed issuer based in France. Shares are quoted on FR FR, under the authority of AMF. Operating in the Healthcare & Pharma sector, INTRASENSE has logged 3 insider filings. Market capitalisation: €12.1m. The latest transaction was reported on 8 June 2023 (Cession). Among the most active insiders: Michèle Lesieur. All data is free.
3
Insider Decl.
0
Thresholds
€5,046
1 ops.
Buy Volume
€4,840
1 ops.
Sell Volume
30Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 June 2023
Declarations3 total
11,000 shares@ €0.44100.0% of flowActionEuronext Paris2023DD914094
4,699 shares@ €0.4429.1% of flowActionEuronext Growth Paris2023DD913463
4,700 shares@ €1.073670.9% of flowActionEuronext Growth Paris2021DD739576
Ideal exit: 25 Dec 2021 (T+270)
3 of 3 declarations
About INTRASENSE
Intrasense is a French medtech company focused on medical imaging software. Founded in 2004 and headquartered in Montpellier, the company designs, develops and markets software solutions for image visualization, post-processing and clinical decision support. Its tools are primarily intended for radiologists, oncologists, surgeons and healthcare institutions. Over time, Intrasense has evolved from a radiology-oriented specialist into a broader clinical imaging platform player, with a particular emphasis on oncology, where it seeks to support diagnosis, treatment planning and patient follow-up. The company’s flagship product is Myrian®, an advanced radiology visualization and multimodal image-processing platform designed to simplify and enhance routine image interpretation. Intrasense has also expanded its portfolio with artificial intelligence-based solutions, including DUOnco™ and Liflow®, which are aimed at oncology applications and longitudinal monitoring of cancer patients. Recent corporate communications indicate that several solutions were certified in 2024, strengthening the regulatory status of the product range and supporting the company’s move toward higher-value clinical offerings. Intrasense is also working toward a more recurring revenue model, with some solutions being commercialized under multi-year subscription arrangements. Intrasense’s market positioning is built on clinical expertise, product innovation and a strong focus on workflow integration for radiologists. The company states that it has 20 years of experience in medical imaging and serves customers internationally, while remaining strongly anchored in France. Its headquarters are located in Montpellier, and its business has been strengthened by industrial partnership. Since June 2023, Guerbet, the French pharmaceutical group active in more than 80 countries, has been the reference shareholder, making Intrasense a subsidiary and reinforcing a strategic alliance centered on AI for medical imaging and oncology. From a financial and strategic standpoint, Intrasense reported 2024 revenue of €2.246 million and presented a roadmap built on four pillars: innovation, product expansion, geographic expansion and financial discipline. Management has set out ambitions for double-digit activity growth in 2025 and break-even by 2027, underscoring the company’s transformation phase. Overall, Intrasense remains a niche specialist at the intersection of medical imaging software, digital health and AI, with a value proposition centered on improving diagnostic accuracy, clinical workflow efficiency and patient care.
